GLP-1 Dosing Guide: Personalized Mg Levels & Genetic Factors

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 dosing ranges from 0.25 mg to 2.4 mg per week for most patients, but the right dose for you depends on individual tolerance, clinical response, and metabolic factors rather than body weight or age alone. Clinical studies show dose escalation protocols reduce side effects while maximizing therapeutic benefit.

Choosing an appropriate GLP-1 dose is a precision-wellness decision, not a one-size-fits-all calculation. Your genetics, baseline metabolic health, and individual receptor sensitivity can influence how your body responds at different dose levels, making personalized assessment essential before treatment begins.

Understanding GLP-1 Dose Ranges and Escalation Protocols

Standard GLP-1 dosing begins at 0.25 mg weekly and increases by 0.25 mg increments every 4 weeks until reaching the therapeutic dose of 1.0 to 2.4 mg weekly. This gradual escalation allows your body to adapt, reducing nausea and gastrointestinal side effects while building tolerance.

Weekly incremental dosing is evidence-based: clinical trials show slower escalation protocols result in better medication adherence and fewer discontinuations due to adverse events. Your provider may adjust the escalation timeline based on your response and tolerability at each stage.

Dosing Framework: Individual Factors Beyond Milligrams

Your optimal GLP-1 dose depends on multiple clinical and metabolic factors, not milligram amount in isolation. Biomarkers including baseline HbA1c, fasting glucose, BMI, gastrointestinal tolerance, and kidney function all inform personalized dosing strategy. This table outlines key considerations your provider should evaluate before recommending a specific dose.

Clinical Factor	How It Influences GLP-1 Dosing
Baseline HbA1c / Fasting Glucose	Higher glucose levels may support faster escalation; prediabetic range may require more cautious titration
Gastrointestinal Tolerance	History of nausea, reflux, or IBS may necessitate slower dose escalation or lower maintenance dose
Kidney Function (eGFR)	eGFR below 30 may require dose adjustments; kidney monitoring recommended during treatment
BMI and Metabolic Rate	Higher BMI typically supports standard 2.4 mg weekly dose; lower BMI may achieve response at 1.0–1.7 mg
Concurrent Medications	Certain antiemetics, diabetes drugs, or cardiovascular agents may influence GLP-1 response and dosing decisions
Genetic Peptide Pathway Predispositions	Variants in GLP1R, GIPR, FTO, and MC4R may provide context for individualized dose response expectations

Genetic Predispositions and Personalized Dose Response

Emerging research indicates that variations in GLP-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) genes may influence receptor sensitivity and dose response. Patients with certain genetic predispositions may achieve therapeutic benefit at lower doses, while others may require standard or higher escalation.

Genetic testing for peptide pathway predispositions cannot predict exact medication response but may help provide context for your provider's dosing discussion. Understanding your genetic profile in GLP1R, GIPR, FTO, and MC4R variants can support a more informed personalized approach to titration and maintenance dosing.

Safety Considerations and Who Should Start GLP-1 Treatment

GLP-1 medications are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe pancreatitis. Caution is warranted in pregnancy, breastfeeding, and severe kidney or heart disease. A comprehensive medical evaluation should precede any dosing decision.

Starting GLP-1 therapy requires baseline assessment of kidney function, liver enzymes, blood glucose, and gastrointestinal health. Your provider should establish a dosing protocol aligned with your clinical status and tolerability. Regular monitoring during dose escalation helps identify optimal dosing and catch potential adverse effects early.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test evaluates key variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) that relate to peptide pathway function and metabolic response. While genetics alone do not determine the ideal milligram dose, these predispositions may help provide context for understanding your baseline receptor sensitivity and dose-response expectations.

The genetic test predicts predispositions in peptide pathways—not exact medication response or guaranteed outcomes. Certain genetic profiles may correlate with faster or slower dose escalation, lower maintenance doses, or heightened gastrointestinal sensitivity at standard dosing. These insights should be interpreted with a qualified healthcare provider as part of a comprehensive clinical assessment.

When combined with your biomarkers (kidney function, baseline glucose, BMI, gastrointestinal history) and clinical goals, genetic context can support a more personalized conversation with your provider about your optimal GLP-1 dosing strategy. This precision-wellness approach helps align treatment selection and titration with your individual biology rather than applying population averages to your care.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.